Advertisement
U.S. markets closed

Cyclacel Pharmaceuticals, Inc. (CYCC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.6500+0.0400 (+1.53%)
At close: 03:57PM EST
2.6700 +0.02 (+0.75%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close2.6100
Open2.6300
Bid2.6600 x 800
Ask2.8800 x 4000
Day's Range2.5803 - 2.7000
52 Week Range2.0000 - 13.6500
Volume11,936
Avg. Volume174,456
Market Cap3.493M
Beta (5Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-29.8500
Earnings DateMar 04, 2024 - Mar 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est93.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYCC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cyclacel Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 02/21/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

    BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024. The Company’s presentation is schedule

  • GlobeNewswire

    Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

    BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company. “We are delighted to h

  • GlobeNewswire

    Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

    BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on January 4, 2024, indicating that the Company has regained compliance with the minimum bid price requirement set forth in R